About 6,202 results
Opioid Use Disorder: Medical Treatment Options
American Family Physician; Coffa, D. et. al.

Sep 30th, 2019 - Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, pat...

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline

Sep 23rd, 2019 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs...

Alarming number of heart infections tied to opioid epidemic

Sep 17th, 2019 - An alarming number of people nationwide are developing infections of either the heart’s inner lining or valves, known as infective endocarditis, in large part, due to the current opioid epidemic. This new trend predominantly affects young, white, poor men who also have higher rates of HIV, hepatitis C and alcohol abuse, according to new research published in the Journal of the American Heart As...

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease

Aug 27th, 2019 - The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure. All these medicines contain a hepatitis C virus (HCV) protease inhibitor and are not indicated for use in patients with moderate to sever...

Treating Hepatitis C in the Family Medicine Office
American Family Physician;

Aug 14th, 2019 - Patient story about being diagnosed with hepatitis C and successful treatment by family doctor.

HIV and Viral Hepatitis - CDC

Jun 26th, 2019 - People with HIV infection are affected disproportionally by viral hepatitis. Nearly 75% of people with HIV who report a history of injection drug use also are infected with hepatitis C virus (HCV).

Hepatitis C Questions and Answers for Health Professionals

Apr 8th, 2019 - What are the case definitions for reportable hepatitis C virus (HCV) infections? The specific viral cause of illness cannot be determined based solely on signs, symptoms, history, or current risk factors, but must be verified by specific serologic testing

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, A. et. al.

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C
Powell, D. et. al.

Feb 3rd, 2019 - The hepatitis C virus is responsible for more deaths in the United States than any other infectious disease, and hepatitis C infections have been rising at an alarming rate since 2010. We evaluated the role of the opioid epidemic and, in particular, the 2010 introduction of an abuse-deterrent version of OxyContin. The OxyContin reformulation led some users of the drug to switch to heroin, which...

Hepatitis, Nonalcoholic Steatohepatitis
Sharma, B. et. al.

Jan 31st, 2019 - Nonalcoholic, fatty liver disease (NAFLD) is defined as the ectopic accumulation of fat in the liver (hepatic steatosis) when no other causes of secondary, liver fat accumulation are present. As minor deposition of fat can occur in healthy adults, deposition of fat in at least 5% of hepatocytes is considered pathologic. Nonalcoholic steatohepatitis (NASH) is diagnosed via a liver biopsy when th...

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
Singal, A. et. al.

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices
Ramsey, S. et. al.

Jan 16th, 2019 - Screening patients with newly diagnosed cancer to identify hepatitis B virus and hepatitis C virus infection before starting treatment may be warranted to prevent viral reactivation and adverse clinical outcomes; universal screening for HIV infection may not be warranted.

Hepatitis C - StatPearls

Oct 26th, 2018 - First diagnosed in 1989, hepatitis C virus (HCV) is a major public health problem affecting 185 million people worldwide. The percentage of people who are seropositive for anti-HCV antibodies worldwide is estimated to have increased from 2.3% to 2.8% between 1990 to 2005.

TECHNIVIE (ombitasvir, paritaprevir and ritonavir) tablets Prescribing Information

TECHNIVIE is a fixed-dose combination of ombitasvir, a hepatitis C virus. NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir

HCV screening risk factors in pregnant women need updating
Heidi Splete

Mar 27th, 2020 - Current risk factors used to screen for hepatitis C should be updated, according to study results of 106,842 pregnant women who underwent screening. Courtesy NIH “Because risk-factor screening has obvious limitations, universal screening in pregnancy has been suggested to allow for linkage to postpartum care and identification of children for future testing and treatment,” wrote Mona Prasad, DO.

The Time to Eradicate Hepatitis C Is Now

Mar 16th, 2020 - It is becoming easier to imagine a world without hepatitis C, thanks to direct-acting antivirals (DAAs) that result in cure rates of over 95% across all genotypes after only 8-12 weeks of oral administration. Dr Harvey J. Alter, the pioneering virologist whose work led to the discovery of hepatitis C virus (HCV), indulged this very same thought in a 2019 lecture. He noted that the concept that ...

Stick with the full 12-week DAA course for acute HCV
M. Alexander Otto, MDedge News

Mar 16th, 2020 - The first randomized trial to see if a short course of a direct-acting antiviral works as well for acute hepatitis C virus (HCV) infection as the standard 12-week course was stopped early after it became clear that it did not, according to a report at the Conference on Retroviruses & Opportunistic Infections. In the end, 6 weeks of sofosbuvir-velpatasvir (Epclusa) “was inferior” to 12 weeks, sa.

Experts recommend testing U.S. adults ages 18-79 for hep C

Mar 2nd, 2020 - (Reuters Health) - With improved effectiveness of hepatitis C treatments, it’s worthwhile to screen U.S. adults for the virus, an expert panel says. The recommendations from the U.S. Preventive Services Task Force (USPSTF), published in JAMA, come as hepatitis C infections are on the rise. The virus can raise the risk of liver cancer and cause cirrhosis, or scarring, of the liver, which can lea...

Screen all adults for hepatitis C, says USPSTF
Heidi Splete

Mar 2nd, 2020 - Adults aged 18-79 years should be screened for hepatitis C virus infection, according to an updated grade B recommendation from the U. S.

USPSTF Recommends HCV Screening for All US Adults Ages 18-79

Mar 1st, 2020 - The US Preventive Services Task Force (USPSTF) today expanded its recommendation for one-time hepatitis C virus (HCV) screening to include all asymptomatic US adults ages 18-79 years, including pregnant women, who do not have known liver disease. It is a B-level recommendation, indicating that the USPSTF "concludes with moderate certainty" that screening for HCV will have a substantial net bene...